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Transduction of recombinant adenovirus into dendritic cells (DCs) is a promising new tool for cancer vaccine development. Here, we
report that an adenovirus vector carrying hepatocellular carcinoma (HCC) antigen HCA661 and infected into DCs generates T-cell
immunity against hepatoma cells. HCA661 is a novel cancer/testis (CT) antigen screened by SEREX from sera of an HCC patient. We
constructed a recombinant adenovirus expressing the full-length cDNA of HCA661 gene and then transduced immature DCs, which
had been generated with GM-CSF and IL-4 from peripheral blood mononuclear cell of HLA-A2
þ healthy donors. The resulting
adenovirus-transduced DCs differentiated in the presence of monocyte-conditioned medium and poly [I]:poly [C], expressing the
surface markers of mature DCs, including CD83, CD80, CD86 and HLA-DR. After maturation, the transduced DCs transcribed
HCA661 mRNA and were able to prime the naı ¨ve T cells to become cytotoxic T lymphocytes (CTLs). Intracellular flow cytometry
and enzyme-linked immunospot assay showed that these CTLs were able to target a hepatoma cell line, HepG2, which is HLA-A2
and HCA661 positive. In summary, we found that this recombinant adenovirus can help to induce DC maturation and these mature
DCs can activate T cells to target hepatoma cells. Therefore, this recombinant adenovirus may have potential for use in liver cancer
immunotherapy.
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Hepatocellular carcinoma (HCC) is the third most common cause
of cancer death in China (Stern et al, 2001). Hepatocellular
carcinoma is one of the most deadly cancers, rarely responding to
conventional treatment such as radiation therapy or chemother-
apy, and usually causing death within a few weeks or months of
detection after diagnosis (Tang, 1989).
Transduction of recombinant adenovirus into dendritic cells
(DCs) is a promising new tool for cancer vaccine development.
Most cancer cells are poor immunogens due to the lack of
costimulatory element B7 or the downregulation of MHC class I
expression, both of which are essential for activation of T cells
(Gong et al, 2000). Therefore, cancer cells do not activate the T-cell
response. On the other hand, DCs are potent antigen-presenting
cells that prime naive cytotoxic T lymphocytes (CTLs) in an HLA-
restricted fashion (Inaba et al, 1986; Steinman, 1991) and have
been shown to induce potent antitumour immunity in vitro and in
vivo (Timmerman and Levy, 1999). Immature DCs such as
Langerhans cells (Romani et al, 1989; Sallusto and Lanzavecchia,
1994) are highly specialised in antigen capture, whereas mature
DCs are migratory cells that play a major role in antigen
presentation (Steinman et al, 1995; Morse et al, 2001). Mature
DCs downregulate endocytotic activity and upregulate MHC class
II and costimulatory molecules, thus enhancing antigen-presenting
capacity for the promotion of T-cell activation. One effective
method of enabling DCs to activate CTL response against cancer
cells is to transfect cancer antigens into DCs via recombinant
adenovirus (Linette et al, 2000). Recombinant adenoviral vectors
have become common in the transduction of tumour antigens into
terminally differentiated and nondividing DCs (Dietz and Vuk-
Pavlovic’, 1998) because of their high efficacy in inducing both
humoral and cell-mediated immune responses (Ertl and Xiang,
1996).
In this study, we used the adenoviral construct based on a E1-
and E3-deleted replication-defective virus of the human strain 5
(Wilson et al, 1994) fused with HCC antigen HCA661. HCA661 is a
novel cancer/testis (CT) antigen screened by SEREX from sera of
HCC patients (Wang et al, 2002). Cancer/testis antigens are
predominantly expressed in cancer tissues, but not in normal
counterparts except in germ cells in testis or ovary (Wang et al,
2002), which has made them very useful in vaccine-based
immunotherapy (Rosenberg, 1999).
Here, we report that (1) recombinant adenovirus (Ad661) was
able to transduce human immature DCs, (2) DCs cultured with
monocyte-condition medium (MCM) and poly [I]:poly [C]
developed phenotypically into mature phenotypes, (3) the mature
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DCs stimulated HCA661-specific CTL response. We demonstrate
that this recombinant adenovirus Ad661 may be a promising
compound for use in liver cancer immunotherapy.
MATERIAL AND METHODS
Culture of HCC cell lines and isolation of peripheral blood
mononuclear cells (PBMCs)
Human HCC HepG2, SMMC-7721, BEL-7402 and QGY-7703 cells
were cultured in RPMI 1640 medium (GIBCO-BRL, USA)
supplemented with 10% heat-inactivated FBS (GIBCO-BRL,
USA), 2mML -glutamine (GIBCO-BRL, USA), 100Uml
 1 penicillin
and 100mgml
 1 streptomycin (GIBCO-BRL, USA).
Peripheral blood mononuclear cells were isolated from freshly
collected buffy coats of healthy donors (Hong Kong Red Cross
Association) by Ficoll–Hypaque (1.077g; Amersham Biosciences,
USA) density gradient centrifugation. The HLA typing of donor
PBMCs was carried out by staining with a mouse anti-HLA-A2
antibody (BB7.2, Amersham Biosciences, USA) using standard
procedures. The PBMCs were washed with PBS and resuspended in
RPMI 1640 supplement with 10% FBS and plated in six-well tissue
culture plates (Falcon, USA) at a density of 2 10
6cellswell
 1 and
incubated at 371C for 2h prior to incubation.
Preparation of mature dendritic cells and human T cells
After 2h incubation, the nonadherent PBMCs were removed by
washing with PBS, and autologous T cells were isolated from these
nonadherent PBMCs by nylon-wool separation according to the
manufacturer’s protocol (Polysciences, USA). The adherent cells
were cultured for 7 days in RPMI 1640 medium supplemented with
10% FBS, 1000Uml
 1 human granulocyte–macrophage colony-
stimulating factor (hGM-CSF; Sandoz Pharma Ltd, China) and
500Uml
 1 hIL-4 (Peprotech, UK). Culture medium and cytokines
were refreshed every other day. On day 7, the nonadherent and
loosely adherent cells were harvested by repeated washes to
generate the immature autologous DC population.
Generation of recombinant adenovirus encoding HCA661
To subclone the human HCA661 cDNA, the plasmid pQE3.1/
HCA661 (Wang et al, 2002) was used as a template for polymerase
chain reaction (PCR) using specific oligonucleotides encompassing
the entire open reading frames. The following PCR primers were
used: human Ad661 sense 50-CGGAATTCATGGCAAAATATGTC
AGT-30, human Ad661 antisense 50-GCTCTAGATTAGT-
CATCCTCGTCATTC TC-30. Polymerase chain reaction was
performed with the following profile: 60s at 951C, 60s at 601C
and 90s at 721C for 30 cycles, followed by a last 10min extension at
721C. The amplified products were cloned into the EcoRI/XbaI
sites of pCR-259 adenovial transfer vector, derived from adeno-
virus type 5 with deleted E1 and E3 regions (Qbiogene, USA) and
then generated the recombinant adenovirus encoding HCA661
(Ad661), according to the protocol of transposed-Ad adenoviral
system stated by the manufacturer (Qbiogene, USA). The
recombinant adenovirus was amplified using QBI-HEK 293 cells
(Qbiogene, USA) and the concentration of the viral titer obtained
was 2 10
9TCID50ml
 1.
Transduction of DCs with recombinant adenovirus
The immature DCs (1 10
5) obtained on day 7 were resuspended
in 50ml cytokine-containing medium and placed as a small drop
into one well of 24-well plates. Recombinant adenovirus was added
at 1000 multiplicity of infection (MOI). The mixture was incubated
at 371C for 2h. Then, the culture medium obtained from day 7
culture containing GM-CSF and IL-4, 25% (vv
 1) MCM and
10mgml
 1 poly [I]:poly [C] (Sigma, USA) was added to make a
total volume of 500ml. The adenovirus QBI-Infectþ (Qbiogene,
USA) containing the lacZ gene for b-galactosidase was used as a
negative control. On day 9, the nonadherent and loosely adherent
cells were harvested by repeated washing and the phenotype of the
mature autologous DCs was identified. Transduction by QBI-
Infectþ was measured by the hydrolysis of Bluo-gal (Invitrogen,
USA). The transfected DCs were washed and irradiated at 30Gy g-
irradiation using g-cell irradiator (Gamma-Elite1000). The irra-
diated cells were stored at  801C for presensitisation of T cells.
The expression of HCA661 gene from transfected DCs was
measured by reverse transcription–polymerase chain reaction
(RT–PCR).
Generation of MCM
Plates (100mm; Falcon, USA) were precoated with an immuno-
globulin (Ig) by adding 5ml of human g-globulin (10mgml
 1;
Calbiochem, USA) for 1h at 371C. After washing with PBS, PBMCs
(1 10
7) in 10ml of complete culture medium were added to the
Ig-coated plates and incubated for 1h at 371C. Nonadherent cells
were removed and the remaining adherent cells were cultured in
fresh complete medium at 371C for 24h. Monocyte-conditioned
media were centrifuged to remove the cell debris and then frozen
at  201C prior to use.
Flow cytometry
Dendritic cells were collected by centrifugation at 1500r.p.m. for
10min and washed with PBS twice. The cells were incubated with
murine mAbs targeting CD83 (Pharmingen, USA), HLA-DR (MHC
class II; Pharmingen, USA), B7-1 (Pharmingen, USA), B7-2
(Pharmingen, USA) or ICAM-1 (Pharmingen, USA) on ice for
1h. After washing the cells with PBS twice, the cells were incubated
with FITC-labelled goat anti-mouse IgG antibody (1:50; Zymed,
USA) and incubated for 30min on ice. After washing with PBS
twice, the cells were resuspended in 0.5ml 2% paraformaldehyde
(Sigma, USA). The fixed cells (10
5 cells per event) were analysed by
FACScan (Becton Dickinson, USA). Cells without the primary Ab
staining antibody were used as a negative control.
Endocytosis assay
Endocytic activity was assessed by measuring uptake of the fluid
phase marker FITC-dextran (MW 4000; Sigma, USA). Immature or
mature DCs (1 10
5) were incubated at 371C in a complete
medium containing 1mgml
 1 FITC-dextran. A control experiment
was performed by incubating the cells at 41C for 1h. After
incubation, the cells were washed twice with ice-cold PBS and then
subjected to flow cytometry analysis (Bell et al, 2001).
Reverse transcription–polymerase chain reaction
The HCA661 mRNA expression of the HepG2 cells and transfected
DCs was assayed by RT–PCR. The mRNA from the cells was
extracted according to the protocol of the mRNA extraction kit
(Roche, Germany). The mRNA was primed with a dT(18)
oligonucleotide at 701C for 5min and put on ice for 2min. The
mRNA was reverse transcribed into cDNA using 200U M-MLV
reverse transcriptase (Promega, USA) at 421C for 1h. HCA661
gene-specific PCR primers were used to amplify the HCA661
fragments of 1kb in length. The following PCR primers were used:
human HCA661 sense 50-CGGAATTCATGCCTCAGAGACCA-30
and human HCA661 antisense 50-GCTCTAGATCAGTCATCCTC-
30. The PCR products were visualised in 1% agarose gel
electrophoresis.
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constructs
The transfected DCs (1 10
5) were washed and cocultured with
HLA-A2-positive T cells (1 10
6cellml
 1) from the same donor in
24-well plates (Falcon, USA). Cells were subcultured twice a week
with complete medium containing IL-2 (20Uml
 1) and IL-7
(10ngml
 1; Peprotech, UK). The irradiated transfected DCs were
added to the plates every week. After incubation for 20 days, the
activated T cells were used as effector cells for intracellular staining
and IFN-g-producing enzyme-linked immunospot ELISPOT assay.
Intracellular staining for IFN-c
The presensitised T cells obtained from one healthy donor were
cocultured with irradiated HepG2 cells at an effector/target ratio of
10:1 for 6h at 371C in the presence of 2mM monensin A
(ebioscience, USA). After incubation, the cells were harvested,
washed with PBS, and stained with FITC-conjugated anti-CD8
(Pharmingen, USA) for 30min at 41C. After washing, the cells were
fixed with 2% paraformaldehyde, and washed once with FACS
buffer and once with permeabilisation buffer (0.1% saponin in
PBS). Subsequently, the cells were stained with PE-conjugated anti-
IFN-g antibody (Pharmingen, USA) for 30min at 41C. Cells were
washed once with permeabilisation buffer and once with FACS
buffer, and then analysed by flow cytometry. Peripheral blood
mononuclear cells obtained from normal volunteers incubated
with 10mgml
 1 of phytohemagglutinin (PHA) were used as a
positive control.
Enzyme-linked immunospot assay
A mAb against human IFN-g (NIB42; Pharmingen, USA) at
10mgml
 1 diluted in carbonated buffer (pH9.5) was coated onto
flat-bottomed 96-well nitrocellulose plates (MultiScreen-HA, Milli-
pore, USA), and incubated overnight at 41C. After washing with
PBS, plates were blocked with RPMI 1640 medium with 10% FBS
for 2h at 371C. HepG2 cells irradiated at 30Gy were applied as
target cells in this experiment. Presensitised T-effector cells
(4 10
5) from two different HLA-A2
þ healthy donors and
irradiated target cells (5 10
4) in complete medium were added
to the plates and incubated for 24h at 371C. Plates were then
washed thoroughly with PBS-Tween 20. A biotinylated anti-IFN-g
antibody (4S.B3; Pharmingen, USA) at a concentration of 1mgml
 1
was added and incubated at room temperature for 2h. After
washing with PBS-Tween six times, a streptavidin–HRP conjugate
antibody (Zymed, USA) at a 1:2000 dilution was added and
incubated at room temperature for 1h. Following washing with
PBS-T six times, spots were developed by adding an AEC substrate
(Sigma, USA) and incubated for 15–20min at room temperature.
Plates were washed with distilled water and air dried. The spots
were then counted under the dissected microscope.
Statistical analysis
Statistical analysis of the spots obtained from ELISPOT assay was
performed with a two-tailed Student t-test. The values of Po0.05
were regarded as significant.
RESULTS
Maturation of DCs transfected with recombinant
adenovirus in MCM and poly [I]:poly [C]
After 7 days culture of adherent monocytes in GM-CSF and IL-4,
immature DCs were generated (Figure 3A) and transfected by
recombinant adenovirus. The transfected DCs were then cultured 2
days in medium containing maturation stimulants, MCM and poly
[I]:poly [C]. Most transfected DCs expressed high levels of CD83
(a maturation marker for DCs), HLA-DR, CD80 and CD86
(Figure 2A). The expression of these surface antigens was
comparable to nontransfected controls (Figure 2B). Also the
morphology of the mature DCs showed more and longer dendrites
protruding out from the cell surface (Figure 3B). The endocytosis
ability of transfected DCs was downregulated (Figure 2C). Our data
showed that the maturation of DCs was not inhibited by adenoviral
transduction. In the control DCs expressing the mature phenotype,
over 90% of the cells expressed b-galactosidase when transfected
with QBI-Infectþ at 1000 MOI as indicated by Bluo-gal staining
(Figure 1B). Thus, the rate of transduction of DCs by recombinant
adenovirus was high.
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Figure 1 (A) Construction of recombinant adenoviruses (Ad661).
HCA661 was cloned into EcoRI/XbaI sites of an adenoviral transfer vector
pCR259 (Qbiogene). (B) (i)Transfection of day 7 immature human DCs
that had been cultured in GM-CSF and IL-4 by QBI-Infectþ (AdenoLacZ)
at an MOI of 1000. Transfected DCs were then cultured for 48h in MCM
and poly [I]:poly [C] for maturation. b-Galactosidase was measured with
Bluo-gal substrate. (ii) DCs matured in MCM and poly [I]:poly [C] without
adenovirus transfection.
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To determine the transcription of HCA661 mRNA, RT–PCR was
performed on RNA obtained from Ad661-transfected DCs.
Dendritic cells were transfected with Ad661 or QBI-Infectþ at
MOI 1000 and cultured for 48h, at which time RNA was extracted.
In DCs transfected with Ad661, HCA661 mRNA was detected
(Figure 3D). In contrast, HCA661 mRNA was not detected in DCs
transfected with QBI-Infectþ (Figure 3D). A b-actin fragment
served as an internal control. In addition, HCA661 mRNA was also
endogenously expressed in HepG2 cells as shown in RT–PCR
(Figure 3C).
Activation of HCA661-specific CTLs by Ad661-transfected
DCs
To generate a specific CTL response against HCA661 expressed on
HepG2 cells, PBMCs from HLA-A2
þ donors were stimulated with
irradiated DCs transfected by Ad661or QBI-Infectþ.
To estimate the frequency of HCA661-specific CTLs after
stimulation with transfected DCs, intracellular flow cytometry
(CytoSpot) assay and ELISPOT assay were used. In the CytoSpot
assay, 6.4% of PBMCs stimulated with Ad661-transfected DCs
stained positive with both anti-IFN-g and anti-CD8 mAbs after
being cocultured with irradiated HepG2 cells for 6h in the
presence of monensin (Figure 4A). In contrast, the PBMCs
stimulated with QBI-Infectþ-transfected DCs or DCs alone
showed only 4.1 and 3.2% positive staining with both anti-IFN-g
and anti-CD8 mAbs, respectively (Figure 4A). The percentage of
HCA661-specifc CTLs was calculated as the number of IFN-
g
þCD8
þ effector T cells reactivated with HepG2 cells (Figure 4A)
deducting the number of IFN-g
þ CD8
þT cells in the cultures
without reactivation with HepG2 cells (Figure 4B). The results
showed that PBMCs presensitised with Ad661-transduced DCs
exhibited 2.3% HCA661-specific CTLs, which is approximately five
times more than that of PBMCs presensitised with QBI-Infectþ-
transduced DCs or DCs alone (0.1 and 0.4% HCA661-specific
CTLs, respectively).
The HCA661-specific T cells have also been identified reliably
with an IFN-g ELISPOT assay in PBMCs from HLA-A2 healthy
positive donors primed with adenovirus-transfected DCs. The
results show that the PBMCs primed with Ad661-transfected DCs
have approximately 400 IFN-g spots, which is four times more
spots than on PBMCs primed with QBI-Infectþ transfected DCs
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Figure 2 Monocytes incubated with GM-CSF and IL-4 developed immature DCs on day 7. After infection with (A) recombinant adenovirus (Ad661) or
(B) without infection, and incubation with MCM and poly [I]:poly [C], the mature DCs were developed within 48h. The expression of DC maturation
markers was determined by FACS with the cells gated in the scatter profile. (C) The DCs (have also been transfected by Ad661) decreased their
endocytosis ability after maturation. Endocytosis was determined by analysis of FITC-dextran internalisation at 37 and 41C (negative control).
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sor DCs alone (Figure 5A and B). These data indicate that Ad661
transfected DCs can stimulate PBMCs to generate IFN-g-secreting
cells, which according to the results of intracellular flow cytometry
are CD8þ T cells (Figure 4). These findings demonstrate the
presence of HCA661 specific CD8þ T cells in PBMCs after
activativion by Ad661-transfected DCs.
DISCUSSION
In the last few years, identification of tumour-associated antigens
(TAAs) (Ja ¨ger et al, 2001) has prompted the development of
different strategies for antitumour vaccination, aimed at inducing
specific recognition of TAA-derived peptides in order to elicit a
persistent immune memory that may eliminate residual tumour
cells and protect recipients from relapses (Bocchia et al, 2000).
Researchers have identified tumour antigens that are expressed
only on cancer cells, and not on normal cells except for germ cells.
These TAAs have been used as targets in immunotherapy.
However, there are some problems associated with TAA peptide-
based immunotherapy. TAA peptides are presented by certain
types of HLA molecules (Sadanaga et al, 2001), Therefore, HLA
typing must be carried out before using a particular TAA peptide-
based immunotherapy.
The present study explores the use of DCs transfected with a
recombinant adenovirus for the treatment of HCC. This approach
can overcome the problem of HLA restriction in TAA-based
immunotherapy. Using viral vectors with genes encoding the full-
length tumour antigens to transfect autologous DCs to activate
both CD4þ and CD8þ T cells makes the typing of HLA
haplotypes unnecessary. In principle, this approach could lead to
an anti-HCC vaccine. Dendritic cells could be generated from
blood of patients and then transfected by recombinant adenovirus
Ad661. The transfected DCs could then activate patients’ T cells to
target the cancer cells in the patient, without concern for HLA
matching.
It has been observed that HCC cells express multiple types of
tumour antigens at the mRNA level, including members of MAGE
family and NY-ESO-1 (Yamashita et al, 1996; Tahara et al, 1999).
The protein of HCA661 is immunogenic and capable of inducing
an antibody response, as it was screened by SEREX from the serum
of an HCC patient (Wang et al, 2002). HCA661 is a CT antigen, as
it does not normally express in human tissues (except testis) and it
expresses at 30% in HCC samples (Wang et al, 2002). The potential
of SEREX-defined CT antigens to induce cellular immunity despite
a low frequency of antibodies in allogenic sera has been confirmed
(Wang et al, 2002). The SEREX-defined NY-ESO-1 can induce a
CTL response and the CTL-defined MAGEA-1 has also been
identified by SEREX (Chen et al, 1998; Jager et al, 2000). This
suggests that SEREX-cloned antigens may contain T- and B-cell
epitopes. These epitopes are capable of inducing either Ab or CTL
responses. In this study, the capacity of HCA661 to elicit a CTL
response has been determined using a recombinant adenovirus to
transduce the full-length HCA661 into DCs.
One reason why the immune system cannot eradicate cancer is
that cancer cells lack the ability to stimulate T-cell activation.
Mature and activated DCs are potent antigen-presenting cells
(APCs) (Chan et al, 2002), which express MHC class I, class II,
costimulatory and adhesion molecules that provide the two
necessary signals for the activation of T-cell populations (Romani
et al, 1989). Recombinant adenovirus technology has been widely
employed in gene therapy and for delivering genes into primary
cell types including murine DCs (Ribas et al, 1997; Song et al, 1997;
Wan et al, 1997). In humans, adenoviral vectors expressing
immunostimulatory cytokines or tumour antigens have recently
been used to elicit antitumour immunity in gene therapy (Molnar-
Kimber et al, 1998; Schuler et al, 1998). However, mature DCs are
less susceptible to transfection than immature DCs (Zhong et al,
1999), due to reduced expression of avb5 integrin (Albert et al,
1998) that mediates the uptake of adenoviruses (Wickham et al,
1993). In our study, we transfected immature DCs with recombi-
nant adenovirus and then induced the DCs to mature by using the
maturation agent. We found that the mRNA of HCA661 was
expressed in the Ad661-transfected DCs (Figure 3D), and ELISPOT
and CytoSpot assays (Figures 4 and 5) demonstrated that the
mature DCs could stimulate HLA-A2
þ CD8þ T cells to target the
HepG2 cells, which are both HLA-A2 and HCA661 positive
(Figure 3C). Our transfected DCs expressed the HCC tumour-
associated antigen HCA661 as well as deleted the fragments of
adenovirus capable of inducing neutralising antibodies against the
adenovirus. These Ad661-transduced DCs have potential applica-
tion for use in immunotherapy.
The development of neutralising antibodies against adenoviral
antibodies following injection of viral vectors is a major problem
in recombinant adenoviral immunotherapy (Christ et al, 1997).
This problem can be avoided by in vitro transduction of DCs. Since
the adenovirus would be internalised, the chance of direct
exposure of viral envelope to the host would be reduced, and
therefore would not be available to B cells.
We found that recombinant adenovirus-mediated transduction
does not inhibit DC maturation (Figure 2). Compared with the DCs
matured by maturation agents only, the adenovirus-transfected
DCs showed a slightly higher expression of DC maturation marker
CD83. The adenovirus may enhance the maturation effect of MCM
and poly [I]:poly [C]. Poly [I]:poly [C] are synthetic viral
polyribonucleotide analogues that mimic a viral danger signal and
are recognised by TOLL 3 receptors on DCs (Verdijk et al, 1999).
A
HCA661
-Actin
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HepG2 SMMC-7721 BEL-7402 QGY-7703
HCA661
DC/661 DC/-gal DC
C
D
B
Figure 3 Cell morphology of (A) immature DCs and (B) mature DCs
(have also been transfected by Ad661) was assessed by microscopy at
100  magnification. (C) Expression of HCA661 mRNA in four HCC cell
lines was analysed by RT–PCR. Gel electrophoresis of RT–PCR products
shows HCA661 transcripts in HepG2, SMMC-7721 and BEL-7402 cells.
Reverse transcription–PCR for b-actin was used to monitor the quality of
the mRNA sample and act as an internal control. (D) Expression of the
transgene HCA661 in the transduced DCs on day 9 was determined by
RT–PCR. Only the DCs transduced by Ad661 show HCA661 mRNA
transcripts; DCs alone and DCs (DC/b-gal) transduced by QBI-Infectþ did
not express HCA661.
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Figure 4 Intracellular flow cytometry assay for detection of IFN-g-expressing CD8
þ T lymphocytes in the PBMCs of HLA-A2
þ donor. The proportion of
IFN-g-secreting CD8
þ T cells are indicated as percentage in the bidimenional flow cytometry diagram. (A) Effector cells with HepG2 cells; (B) effector cells
only.
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Figure 5 Presensitisation of PBMCs from HLA-A2
þ donors (A and B). Peripheral blood mononuclear cells were presensitised with irradiated DCs
transduced by Ad661, QBI-Infectþ (b-gal) or DCs alone and tested against the HLA-A2
þ target cell, HepG2 on day 19 using ELISPOT. Results represent
the mean number of spots per 40000 effector PBMCs in duplicate wells, with error bars indicating standard deviation. Differences between paired cultures
were compared by two-tailed Student’s t-test for paired samples (Po0.05).
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for maturation. However, the adenovirus itself does not drive the
maturation of immature DCs without MCM and poly [I]:poly [C]
(data not shown). In human monocyte-derived DCs, mature
DCs are less susceptible to transfection than immature DCs,
because immature DCs selectively express the avb5 integrin that
mediates the uptake of adenoviruses (Zhong et al, 1999). Our
findings suggest that in vitro transfection of immature DCs
with adenovirus does not affect its further development into
mature DCs. Our adenovirus-transfected DCs showed a greater
than 90% transfection efficiency for the reporter gene expression
(Figure 1B) and also displayed mature DCs phenotypes (Figures 2A
and 3B).
We conclude that human monocyte-derived immature DCs
transfected with recombinant adenovirus Ad661 ex vivo and
developed into mature DCs with MCM and poly [I]:poly [C] were
found to express HCA661 and to induce HCA661-specific CTL
reaction. Ad661 may be a promising compound for use in the
immunotherapy of HCC.
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